There is confirmation that the European Union’s pharmaceuticals authority has received an application from Novavax, an American biotechnology company, to enable the company’s coronavirus vaccine to be used in the EU. If the idea is adopted, it has the potential to result in a significant boost in vaccination supplies throughout the continent.
The EMA Has Approved The COVID Vaccine Applied For By Novavax
On Wednesday, the European Medicines Agency announced that it had begun analyzing data submitted by Novavax for their two-dose immunization, which is presently being reviewed. It is possible, according to the Food and Drug Administration, that an expedited review method may result in a decision within weeks “if the data submitted are sufficiently robust and comprehensive to support the efficacy, safety, and quality of the vaccine.
A distinct approach was used to generate the COVID-19 vaccine developed by Novavax, as opposed to other vaccinations now available on the market, such as those made by AstraZeneca and Johnson & Johnson, as well as messenger RNA vaccines developed by Moderna and Pfizer-BioNTech, among others.
Novavax’s injection aims to elicit an immune response against the coronavirus by using lab-grown copies of the spike protein that protects the virus from infection. According to the Maryland-based vaccine manufacturer Novavax, a study of over 30,000 patients in the United States and Mexico found that the immunization was around 90 percent effective against symptomatic COVID-19 in the summer of 2016. According to the company, it also operated against the variances that were common in those countries at the time of the experimentation. In addition to discomfort at the injection site, the company noted that mild side effects included headaches, aches and pains, and fatigue.
Some of the firms whose vaccines have been authorized by the European Medicines Agency include Pfizer-BioNTech, Moderna Pharmaceuticals, AstraZeneca, and Johnson & Johnson (EMA). The vaccinations in question were produced by companies such as Sinovac of China, Sanofi Pasteur of France, and Sputnik V of Russia. In a previous statement, Novavax claimed that it would prioritize obtaining approval in underdeveloped nations since their vaccine is more easily transported; Indonesia just granted approval for the vaccine. The vaccine is now pending clearance from the World Health Organization and from countries such as the United Kingdom, Australia, and Canada, amongst other organizations and governments.
According to the World Health Organization, European nations, which have validated more than two-thirds of the COVID-19 cases recorded internationally in the preceding week, are now at the epicenter of the pandemic. The United States government is considering reimposing lockdown restrictions and seeking to accelerate vaccination efforts, according to government sources there. In October, Novavax replied to concerns that the company’s vaccine production had been delayed due to a paucity of raw materials and other difficulties encountered throughout the manufacturing process. Because of partnerships with organizations such as the Serum Institute of India, SK Bioscience in South Korea, and Takeda in Japan, the company announced that it planned to have “a capacity of 150 million doses per month” by the end of the fourth quarter.
